Truist Securities Reiterates Buy Rating on BioMarin Pharmaceutical (BMRN), Guidance Indicates Strong Demand for Voxzogo
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $135.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
